🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
21.73
-0.98 (-4.32%)
At close: Nov 20, 2026, 4:00 PM EST
22.00
+0.27 (1.24%)
After-hours: Nov 20, 2026, 7:41 PM EST

Tango Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
-62.3842.0736.5324.8637.04
Revenue Growth
-48.29%15.17%46.93%-32.89%383.83%
Cost of Revenue
151.76132.17143.92115.2105.9177.64
Gross Profit
-151.76-69.78-101.85-78.67-81.05-40.59
Selling, General & Admin
76.7741.5143.7535.530.0317.6
Operating Expenses
76.7741.5143.7535.530.0317.6
Operating Income
-228.54-111.29-145.6-114.17-111.07-58.19
Interest & Investment Income
14.735.637.896.621.460.5
Other Non Operating Income (Expenses)
3.44.077.615.941.49-0.25
Pretax Income
-208.05-101.59-130.09-101.61-108.12-57.94
Income Tax Expense
-0.0500.210.130.050.29
Net Income
-208-101.59-130.3-101.74-108.18-58.24
Net Income to Common
-208-101.59-130.3-101.74-108.18-58.24
Net Income Growth
------
Shares Outstanding (Basic)
151116109958862
Shares Outstanding (Diluted)
151116109958862
Shares Change
36.56%6.35%15.50%7.69%41.40%94.50%
EPS (Basic)
-1.38-0.87-1.19-1.08-1.23-0.94
EPS (Diluted)
-1.38-0.87-1.19-1.08-1.23-0.94
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-150.36-139.93-132.26-119.51-116.77-61.36
Free Cash Flow Per Share
-1.00-1.21-1.21-1.26-1.33-0.99
Gross Margin
--111.86%-242.10%-215.38%--109.59%
Operating Margin
--178.39%-346.09%-312.57%-446.79%-157.09%
Profit Margin
--162.85%-309.73%-278.55%-435.14%-157.21%
Free Cash Flow Margin
--224.31%-314.38%-327.18%-469.72%-165.66%
EBITDA
-226.75-109.01-143.1-111.76-109.46-57.29
EBITDA Margin
--174.74%----154.67%
D&A For EBITDA
1.792.282.52.421.610.9
EBIT
-228.54-111.29-145.6-114.17-111.07-58.19
EBIT Margin
--178.39%----157.09%
Revenue as Reported
62.3862.3842.0736.5324.8637.04
SEC Filings: 10-K · 10-Q